MAPT and Brain atrophy: No significant differences are evident among sAD and rpAD patients regarding brain atrophy, hippocampal volume, genetic determinants, molecular hallmarks, neurological symptoms, or CSF biomarkers (tau, phospho-tau, Aβ40, and Aβ42).